Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis, Crohn’s disease, and axial spondylitis; Xdivane, a nivolumab biosimilar candidate, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma. The company was incorporated in 2008 and is headquartered in Solna, Sweden.
Metrics to compare | XBRANE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXBRANEPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.0x | −2.9x | −0.5x | |
PEG Ratio | −0.01 | −0.03 | 0.00 | |
Price/Book | 1.3x | 2.1x | 2.6x | |
Price / LTM Sales | 1.4x | 6.6x | 2.9x | |
Upside (Analyst Target) | 177.8% | 209.3% | 64.0% | |
Fair Value Upside | Unlock | 28.3% | 9.4% | Unlock |